🕵️ LB Pharmaceuticals Inc ($LBRX)
SEC insider & ownership activity, last 12 months · CIK 1691082 · every row links its SEC filing
Insider buy value was withheld pending verification over the last 12 months. DEEP Track Capital, LP trimmed 14.9% → 11.7%. No red-flag 8-Ks in the window.
Insider flow
1 buyer, value withheld pending verification (3 lots) · 0 sellers, $0 (0 lots)
| Insider | Buys | Bought | Sells | Sold | Last |
|---|---|---|---|---|---|
| DEEP Track Biotechnology Master Fund, Ltd. | 3 | value withheld pending verification | 0 | – | Jul 30, 2026 |
5%+ holders
| Holder | Stake | Class | Schedule | Event | |
|---|---|---|---|---|---|
| David Kroin | 11.7% | 13D | Feb 6, 2025 | filing ↗ | |
| DEEP Track Capital, LP | 11.7% | 13D | Feb 6, 2025 | filing ↗ | |
| DEEP Track Biotechnology Master Fund, Ltd. | 9.4% | 13D | Feb 6, 2025 | filing ↗ | |
| RA Capital Management, L.P. | 8.7% | 13G | Feb 17, 2026 | filing ↗ | |
| Peter Kolchinsky | 8.7% | 13G | Feb 17, 2026 | filing ↗ | |
| Rajeev Shah | 8.7% | 13G | Feb 17, 2026 | filing ↗ | |
| RA Capital Healthcare Fund, L.P. | 8.7% | 13G | Feb 17, 2026 | filing ↗ | |
| Commodore Capital LP | 6.8% | 13G | May 15, 2026 | filing ↗ | |
| Commodore Capital Master LP | 6.8% | 13G | May 15, 2026 | filing ↗ | |
| Robert Egen Atkinson | 6.8% | 13G | May 15, 2026 | filing ↗ | |
| Michael Kramarz | 6.8% | 13G | May 15, 2026 | filing ↗ | |
| BlackRock, Inc. | 6.3% | 13G | Jul 29, 2026 | filing ↗ | |
| Pontifax Vi G.p. L.p. | 6.3% | 13D | Sep 12, 2025 | filing ↗ | |
| Ran Nussbaum | 6.3% | 13D | Sep 12, 2025 | filing ↗ | |
| Tomer Kariv | 6.3% | 13D | Sep 12, 2025 | filing ↗ | |
| Pontifax Management 4 G.P. (2015) Ltd. | 6.3% | 13D | Sep 12, 2025 | filing ↗ | |
| JPMorgan Chase & Co | 5.2% | 13G | Jul 16, 2026 | filing ↗ | |
| Caligan Partners LP | 5.0% | 13G | May 15, 2026 | filing ↗ | |
| Johnson David Edward | 5.0% | 13G | May 15, 2026 | filing ↗ | |
| Trails EDGE Capital Partners, LP | 5.0% | 13G | Dec 31, 2025 | filing ↗ | |
| Trails EDGE Biotechnology Master Fund, LP | 5.0% | 13G | Dec 31, 2025 | filing ↗ | |
| Ortav Yehudai | 5.0% | 13G | Dec 31, 2025 | filing ↗ | |
| TCG Crossover GP II, LLC | 5.0% | 13G | Aug 14, 2026 | filing ↗ | |
| TCG Crossover Fund II, L.P. | 5.0% | 13G | Aug 14, 2026 | filing ↗ | |
| Chen Yu | 5.0% | 13G | Aug 14, 2026 | filing ↗ |
Planned insider sales (Form 144)
| Seller | Planned | Approx. sale date | |
|---|---|---|---|
| Prensky Zachary | $487K | Jun 9, 2026 | filing ↗ |
Material events (8-K)
| Item | Event date | |
|---|---|---|
| Officer/director changes (5.02) | Sep 15, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Sep 15, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Sep 15, 2026 | filing ↗ |
| Officer/director changes (5.02) | Sep 3, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Sep 3, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Sep 3, 2026 | filing ↗ |
| Earnings (2.02) | Aug 11, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Aug 11, 2026 | filing ↗ |
| Material agreement (1.01) | Jul 28, 2026 | filing ↗ |
| Unregistered equity sale (3.02) | Jul 28, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Jul 28, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jul 28, 2026 | filing ↗ |
| Other events (8.01) | Jul 22, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jul 22, 2026 | filing ↗ |
| Officer/director changes (5.02) | Jun 8, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jun 8, 2026 | filing ↗ |
| Shareholder vote (5.07) | Jun 3, 2026 | filing ↗ |
| Earnings (2.02) | May 12, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | May 12, 2026 | filing ↗ |
| Earnings (2.02) | Mar 26, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Mar 26, 2026 | filing ↗ |
| Officer/director changes (5.02) | Mar 13, 2026 | filing ↗ |
| Officer/director changes (5.02) | Mar 4, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Mar 4, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Mar 4, 2026 | filing ↗ |
| Material agreement (1.01) | Feb 4, 2026 | filing ↗ |
| Unregistered equity sale (3.02) | Feb 4, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Feb 4, 2026 | filing ↗ |
| Other events (8.01) | Feb 4, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Feb 4, 2026 | filing ↗ |